Clinical trials: Pioglitazone, completed
Intracerebral Hemorrhage
Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is a devastating disease with less than 20% of survivors being independent at 6 months. There is currently no approved treatment for ICH which has been shown to improve outcomes.
- Trial name
- SHRINC (NCT00827892)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- The University of Texas Health Science Center, Houston
Obesity, Sarcopenia
Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle
Obesity in humans has been shown to result in the increased release of small inflammatory-inducing proteins, called cytokines, from the fat cells of the body.
- Trial name
- NCT02305069
- Testing
- Pioglitazone, Insulin, Octreotide
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Metabolic Syndrome
Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic syndrome: aetiology, pathogenesis, diagnosis, clinical management and prognosis
- Trial name
- DRWMNTMS (NCT02503865)
- Testing
- Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin, "Analimentary detoxication"
- Where
- Kazakhstan
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Nazarbayev University
Diabetes Mellitus, Type 2
Incretin-based Drugs and Pancreatic Cancer
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone in or combination with other anti-diabetic drugs are associated with an increased risk of pancreatic cancer…
- Trial name
- NCT02475499
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas
- Where
- Canada
- Volunteers
- 886,172 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type 2 Diabetes
Pioglitazone and Metformin in Diabetic Children
HYPOTHESIS: Treatment with pioglitazone is more effective in reducing resistin concentrations and insulin resistance than metformin in children with Type 2 Diabetes (T2D).
- Trial name
- NCT01396564
- Testing
- Metformin, Pioglitazone
- Where
- Mexico
- Volunteers
- 56 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Type 2 Diabetes
Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone
This study will assess the safety and efficacy of adding nateglinide to treatment with basal insulin glargine, metformin and/or thiazolidinedione (pioglitazone or rosiglitazone), for patients with type 2 diabetes who are not…
- Trial name
- NCT00402909
- Testing
- Nateglinide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation.
- Trial name
- NCT03492580
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 714,582 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus
People with type 2 diabetes mellitus (earlier known as maturity onset diabetes mellitus) have high blood levels of sugar and fat.
- Trial name
- NCT00308373
- Testing
- Metformin vs Thiazolidinedione (Pioglitazone)
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Bipolar Disorder, Major Depressive Disorder
Pioglitazone and Quetiapine XR Pharmacogenetic Study
Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program.
- Trial name
- NCT01342380
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University Hospitals Cleveland Medical Center
Type II Diabetes Mellitus
Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy
The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg on glycemic control when used in participants with inadequately controlled type 2 diabetes mellitus treated with stable combinations of metformin and…
- Trial name
- ADD (NCT01972724)
- Testing
- Pioglitazone, Metformin, Sulfonylurea
- Where
- 9 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- Takeda
Parkinson's Disease
Pioglitazone in Early Parkinson's Disease
This is a multi-center, double-blind, placebo controlled clinical trial of two dosages of oral pioglitazone (15 milligram(mg) and 45 milligram (mg)) for safety, tolerability, and futility.
- Trial name
- NCT01280123
- Testing
- Pioglitazone
- Where
- 38 sites in United States
- Volunteers
- 210 people
- Sponsor
- University of Rochester
Diabetes
Pioglitazone on Cardiac Function and Large Arteries (PICCOLA Study)
This study aims to use a novel, sensitive, non-invasive scanning technique to investigate the effects of insulin-sensitizing agent pioglitazone, on heart and artery function.
- Trial name
- PICCOLA (NCT00485056)
- Testing
- Pioglitazone
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Imperial College London
Chronic Hepatitis C
Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone
The aim of this study is to investigate the efficacy and safety of an insulin-sensitizer (Actos) added to a standard Pegasys/Copegus combination therapy of chronic hepatitis C in patients who have previously failed a…
- Trial name
- NCT00433069
- Testing
- Pioglitazone, Interferon Alfa-2a, Ribavirin
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- University Hospital, Geneva
Polycystic Kidney Disease
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Funding Source - FDA OOPD Pioglitazone is currently used in clinical practice to treat diabetes and this study will examine the potential use of a low dose of the same drug for the treatment of polycystic kidney disease.
- Trial name
- PIOPKD (NCT02697617)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Diabetes Mellitus
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and glimepiride combination therapy compared to glimepiride monotherapy in subjects with Type 2 Diabetes.
- Trial name
- NCT00770952
- Testing
- Pioglitazone and Glimepiride, Glimepiride
- Where
- 17 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Takeda
Obesity, Type 2 Diabetes
Pioglitazone on Pancreatic Steatosis and Bone Health
Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers.
- Trial name
- NCT00855010
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Texas Southwestern Medical Center
T2DM
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
- Trial name
- CT-L03 (NCT06571591)
- Testing
- CT-L03 Group 1, CT-L03 Group 2, Empagliflozin
- Where
- South Korea
- Volunteers
- 606 people
- Sponsor
- Celltrion
Type 2 Diabetes
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.
- Trial name
- RAISE (NCT00575874)
- Testing
- Rivoglitazone HCl, pioglitazone HCl
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Type II Diabetes Mellitus
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
Mitochondrial dysfunction in skeletal muscle results in decreased muscle fatty acid oxidation, leading to conversion of fatty acids into triglycerides and its accumulation inside the muscle tissue.
- Trial name
- PIO (NCT01165190)
- Testing
- pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Arizona State University